281 related articles for article (PubMed ID: 35401202)
1. Glutamate Scavenging as a Neuroreparative Strategy in Ischemic Stroke.
Kaplan-Arabaci O; Acari A; Ciftci P; Gozuacik D
Front Pharmacol; 2022; 13():866738. PubMed ID: 35401202
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism of neuroprotection: Blood glutamate grabber.
Castillo J; Loza MI; Mirelman D; Brea J; Blanco M; Sobrino T; Campos F
J Cereb Blood Flow Metab; 2016 Feb; 36(2):292-301. PubMed ID: 26661174
[TBL] [Abstract][Full Text] [Related]
3. Rescuing ischemic stroke by biomimetic nanovesicles through accelerated thrombolysis and sequential ischemia-reperfusion protection.
Yu W; Yin N; Yang Y; Xuan C; Liu X; Liu W; Zhang Z; Zhang K; Liu J; Shi J
Acta Biomater; 2022 Mar; 140():625-640. PubMed ID: 34902617
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke.
da Silva-Candal A; Pérez-Díaz A; Santamaría M; Correa-Paz C; Rodríguez-Yáñez M; Ardá A; Pérez-Mato M; Iglesias-Rey R; Brea J; Azuaje J; Sotelo E; Sobrino T; Loza MI; Castillo J; Campos F
Ann Neurol; 2018 Aug; 84(2):260-273. PubMed ID: 30014516
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacology of neuroprotection in acute ischemic stroke].
Fernández-Gómez FJ; Hernández F; Argandoña L; Galindo MF; Segura T; Jordán J
Rev Neurol; 2008 Sep 1-15; 47(5):253-60. PubMed ID: 18780272
[TBL] [Abstract][Full Text] [Related]
6. Disrupted Ionic Homeostasis in Ischemic Stroke and New Therapeutic Targets.
Hu HJ; Song M
J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2706-2719. PubMed ID: 29054733
[TBL] [Abstract][Full Text] [Related]
7. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
8. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Roncal C; Martinez de Lizarrondo S; Salicio A; Chevilley A; Rodriguez JA; Rosell A; Couraud PO; Weksler B; Montaner J; Vivien D; Páramo JA; Orbe J
Cardiovasc Res; 2017 Aug; 113(10):1219-1229. PubMed ID: 28379489
[TBL] [Abstract][Full Text] [Related]
9. The case for neuregulin-1 as a clinical treatment for stroke.
Noll JM; Sherafat AA; Ford GD; Ford BD
Front Cell Neurosci; 2024; 18():1325630. PubMed ID: 38638304
[TBL] [Abstract][Full Text] [Related]
10. A novel cell-penetrating peptide targeting calpain-cleavage of PSD-95 induced by excitotoxicity improves neurological outcome after stroke.
Ayuso-Dolado S; Esteban-Ortega GM; Vidaurre ÓG; Díaz-Guerra M
Theranostics; 2021; 11(14):6746-6765. PubMed ID: 34093851
[TBL] [Abstract][Full Text] [Related]
11. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: Applications for natural compounds from medicinal herbs.
Zhu T; Wang L; Wang LP; Wan Q
Biomed Pharmacother; 2022 Apr; 148():112719. PubMed ID: 35168073
[TBL] [Abstract][Full Text] [Related]
13. Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective.
Yang XM; Yu H; Li JX; Li N; Li C; Xu DH; Zhang H; Fang TH; Wang SJ; Yan PY; Han BB
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38662299
[TBL] [Abstract][Full Text] [Related]
14. Ischemic neuronal damage.
Taoufik E; Probert L
Curr Pharm Des; 2008; 14(33):3565-73. PubMed ID: 19075733
[TBL] [Abstract][Full Text] [Related]
15. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
Ma H; Jiang Z; Xu J; Liu J; Guo ZN
Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
[TBL] [Abstract][Full Text] [Related]
16. Excitotoxicity and stroke: identifying novel targets for neuroprotection.
Lai TW; Zhang S; Wang YT
Prog Neurobiol; 2014 Apr; 115():157-88. PubMed ID: 24361499
[TBL] [Abstract][Full Text] [Related]
17. Brain to blood glutamate scavenging as a novel therapeutic modality: a review.
Boyko M; Gruenbaum SE; Gruenbaum BF; Shapira Y; Zlotnik A
J Neural Transm (Vienna); 2014 Aug; 121(8):971-9. PubMed ID: 24623040
[TBL] [Abstract][Full Text] [Related]
18. The interplay of microRNAs and post-ischemic glutamate excitotoxicity: an emergent research field in stroke medicine.
Majdi A; Mahmoudi J; Sadigh-Eteghad S; Farhoudi M; Shotorbani SS
Neurol Sci; 2016 Nov; 37(11):1765-1771. PubMed ID: 27350638
[TBL] [Abstract][Full Text] [Related]
19. Excitatory and inhibitory amino acid neurotransmitters in stroke: from neurotoxicity to ischemic tolerance.
Amantea D; Bagetta G
Curr Opin Pharmacol; 2017 Aug; 35():111-119. PubMed ID: 28826602
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
